About

Achyut Healthcare Ltd operates in the pharmaceuticals subsector of healthcare. The company has a market cap of ₹170.43 Cr, positioning it as a smaller-scale player in the Indian pharma space. It faces operational losses, with negative operating margins (-7.21%), raising questions about its business model or profitability path.

Face value: ₹1

Market cap

₹143 Cr

P/E

445.8×

P/B

4.1×

Dividend yield

0%

ROE

1%

ROCE

1.2%

Debt / equity

0

OPM

1.5%

EPS (TTM)

₹0.0

Book value

₹1.5

52-week high

₹9.1

52-week low

₹4.9

Key insights

Company research notes and source-linked reviews

Key risks

OPM of -7.21% creates operational cash burn; verify timeline to profitability and funding sources.
PE ratio of 309.87 is unsustainably high; verify whether latest results justify earnings growth expectations.
Zero DII and 5.13% FII suggest domestic skepticism while foreign investors show interest; verify broker research on competitive positioning.
Market cap ₹170.43 Cr limits analyst coverage and liquidity; verify disclosure adequacy and stock trading depth.

Generated analysis · source review pending

Growth drivers

Market cap ₹170.43 Cr is small for pharma; verify whether latest results show revenue scale-up.
OPM of -7.21% is the binding constraint; verify whether latest results show path to margin recovery.
1-year return of 83.85% prices in earnings growth; verify whether latest results validate this expectation.
FII holding 5.13% vs DII at 0% suggests foreign optimism; verify whether FII research cites specific catalysts.

Generated analysis · source review pending

₹5.9+18.2%1Y

Beta

0.71

Damps index moves

Volatility (1y)

51.8%

Annualised, daily returns

RSI (14)

11.4

Oversold territory

Rel. strength (1y)

6.2%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Revenue CAGR of 62.5% over the last 3 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 10.3×

Cons

−Low return on equity of 1.8% (3-yr avg)
−Thin operating margin of 1.5%
−Expensive at 445.8× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

39/100

Business quality: 33
Growth: 69
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	3	6	3	12
COGS	3	2	—	—	10
Gross profit	1	1	—	—	2
	1	1	6	3	1
	-0	-0	0	-0	0
OPM %	-0.7%	-10%	0.3%	-7.2%	1.5%
Depreciation	0	0	—	—	0
Interest	0	0	0	0	0
	0	1	1	1	0
Profit before tax	0	0	1	1	0
Tax	0	0	0	0	0
Tax %	60%	25.8%	23%	22.9%	15.8%
	0	0	1	1	0
PAT margin %	1%	8.5%	9.3%	18%	2.8%
EPS (₹)	0.2	0	0.3	0	0
EPS adjusted (₹)	0	0	0	0	0
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	7	9	17	24	24
Reserves	2	5	14	8	11
	—	—	—	—	0
	1	1	0	1	3
Total equity & liabilities	10	15	31	33	38
	0	0	0	0	0
CWIP	—	3	9	18	28
Investments	2	1	—	—	0
	8	14	22	14	10
Total assets	10	15	31	33	38

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-7	0	-0	-4	1
	-2	-5	-15	5	-2
	9	5	16	-0	3
Net cash flow	0	-0	0	1	2
Free cash flow	-7	-3	-6	-15	-7
CFO / Operating profit %	—	—	—	—	664.7%

Compounded sales growth

7 years: —
5 years: —
3 years: 63%
1 year: 280%

Compounded profit growth

7 years: —
5 years: —
3 years: 12%
1 year: -42%

Stock price CAGR

10 years: —
5 years: —
3 years: —
1 year: 15%

Return on equity

7 years: —

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	18%	27.4%	—	—	14.2%
EBITDA margin %	-0.7%	-10%	0.3%	-7.2%	1.5%
EBIT margin %	-1%	-10.4%	0.3%	-7.2%	0.3%
PAT margin %	1%	8.5%	9.3%	18%	2.8%
Working capital
Receivable days	18	37	24	160	46
Inventory days	14	60	4	21	16
Payable days	19	—	—	—	44
NWC days	14	—	—	—	17
Leverage
Current ratio	9.43	12.62	107.35	9.35	4.59
Debt to EBITDA	—	—	—	—	0
Debt to equity	—	—	—	—	0
Interest coverage	—	—	—	—	10.3
Asset turnover	0.41	0.18	0.2	0.09	0.3
Return ratios
Return on assets %	0.4%	1.5%	1.8%	1.7%	0.8%
Return on capital employed %	1.1%	2.6%	3.3%	2.3%	1.2%
Return on equity %	0.4%	1.6%	1.9%	1.8%	0.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Dec 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	53.77%	53.77%	53.77%	44.8%	44.8%	46.11%	46.11%	46.38%	47.07%	47.71%	47.4%	47.4%
	0%	0%	0%	0%	0%	6.14%	8.14%	6.14%	5.26%	5.26%	5.13%	5.13%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	46.23%	46.23%	46.23%	55.2%	55.2%	47.75%	45.75%	47.48%	47.67%	47.03%	47.47%	47.47%
No. of shareholders	—	—	—	—	—	—	—	—	565	514	1,905	3,174

Promoter holding down 6.37 percentage points since Dec 2022.

86 deals · 30 Mar 2022 – 5 May 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
5 May 2025	KHODEEAR ENTERPRISE LLP LLP	Bulk	BSE	Buy	15,75,000	₹3.48	₹0.55 Cr
2 May 2025	MULTITUDE GROWTH FUNDS LIMITED	Bulk	BSE	Sell	22,99,500	₹3.55	₹0.82 Cr
27 Mar 2025	KHODEEAR ENTERPRISE LLP LLP	Bulk	BSE	Buy	30,87,000	₹3.15	₹0.97 Cr
27 Mar 2025	FLYONTRIP SERVICES PRIVATE LIMITED .	Bulk	BSE	Sell	15,43,500	₹3.15	₹0.49 Cr
27 Mar 2025	FLYONTRIP SERVICES PRIVATE LIMITED	Bulk	BSE	Sell	12,28,500	₹3.15	₹0.39 Cr
9 Dec 2024	FLYONTRIP SERVICES PRIVATE LIMITED	Bulk	BSE	Sell	1,48,500	₹80.02	₹1.19 Cr
25 Nov 2024	FLYONTRIP SERVICES PRIVATE LIMITED	Bulk	BSE	Sell	3,51,000	₹74.80	₹2.63 Cr
25 Nov 2024	AG DYNAMIC FUNDS LIMITED	Bulk	BSE	Buy	3,37,500	₹74.80	₹2.52 Cr
25 Nov 2024	FLYONTRIP SERVICES PRIVATE LIMITED	Bulk	BSE	Buy	11,250	₹74.80	₹0.08 Cr
17 Oct 2024	FLYONTRIP SERVICES PRIVATE LIMITED	Bulk	BSE	Sell	87,750	₹65.00	₹0.57 Cr

1–10 of 86

1 / 9

Mr. MAHENDRA CHATRABHUJ RAYCHANon-Executive - Non Independent Director-Chairperson related to Promoter
Mr. JIGEN JAGDISHBHAI MODIExecutive Director-MD
Mrs. AMISHA JIGEN MODIExecutive Director
Mr. AKSHIT MAHENDRA RAYCHANon-Executive - Non Independent Director
Mr. RUTVIK SANJAYKUMAR THAKKARNon-Executive - Independent Director
Mr. SONU LALITKUMAR JAINNon-Executive - Independent Director
Mr. RAJESH CHINUBHAI SUTARIANon-Executive - Independent Director
Mr. PARAG KUMAR SANDIPKUMAR DAVENon-Executive - Independent Director
Mr. Kaushalkumar Shrikrishnabhai DaveCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Achyut Healthcare Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

4

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results13 Aug 2026

1

Face value ₹10 → ₹110 Dec 2024 · ex-date

2

Bonus 4:1010 Dec 2024 · ex-date
Bonus 1:225 Apr 2023 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

20 announcementsExport CSV

30 Sept 2026, 6:52 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Sept 2026, 6:48 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Sept 2026, 6:46 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Sept 2026, 6:38 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

29 Sept 2026, 12:55 pmCompany Update

Outcome Of AGM

General PDF

29 Sept 2026, 12:50 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

5 Sept 2026, 3:51 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

5 Sept 2026, 3:28 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

Date	Category	Subject	Filing
30 Sept 2026, 6:52 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
30 Sept 2026, 6:48 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management

Loading announcements…

Achyut Healthcare Ltd

Achyut Healthcare Ltd

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Stock splits1

Bonus issues2

Announcements

Not in the F&O segment

Board meetings1

Stock splits1

Bonus issues2

Ratio timeline

No fund holdings on record

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1

2

1

1

2